Daily Endocrinology Research Analysis
Analyzed 42 papers and selected 3 impactful papers.
Summary
Three high-impact studies span prevention and mechanisms in endocrinology: a prespecified subgroup of the VESALIUS-CV randomized trial shows evolocumab prevents first major cardiovascular events in high-risk patients with diabetes but without known atherosclerosis; a Cell Metabolism study links the common food additive maltol to diabetic fragility fractures via dual effects on bone remodeling; and a preclinical study identifies dopamine signaling as a driver of hypoglycemia-associated autonomic failure, with metoclopramide restoring counterregulation in rodents.
Research Themes
- Primary prevention of cardiovascular events in diabetes using PCSK9 inhibition
- Dietary additive–bone remodeling interactions under hyperglycemia
- Neuroendocrine mechanisms of hypoglycemia unawareness and therapeutic repurposing
Selected Articles
1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
In a prespecified subgroup of 3655 high-risk patients with diabetes but without known significant atherosclerosis, evolocumab reduced first MACE (HR 0.69 for both 3- and 4-point MACE) over a median 4.8 years and lowered all-cause mortality (HR 0.76). LDL-C fell to a median 52 mg/dL at 48 weeks versus 111 mg/dL with placebo.
Impact: This randomized, placebo-controlled evidence extends PCSK9 inhibition to primary prevention in high-risk diabetes without established atherosclerosis, demonstrating significant event reduction.
Clinical Implications: For high-risk patients with diabetes lacking known significant atherosclerosis, adding evolocumab to statins can reduce first MACE; clinicians may consider PCSK9 inhibition for primary prevention in this population after individualized risk–benefit assessment and cost/access considerations.
Key Findings
- Evolocumab reduced 5-year 3-point MACE (HR 0.69; P=0.009) and 4-point MACE (HR 0.69; P=0.001) versus placebo.
- All-cause mortality was lower with evolocumab (HR 0.76; 5-year KM 7.8% vs 10.1%).
- LDL-C reduction at 48 weeks was substantial (median 52 mg/dL vs 111 mg/dL in placebo) on top of statins.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design across 33 countries with long median follow-up (4.8 years).
- Prespecified subgroup with clear inclusion criteria and robust lipid substudy documenting on-treatment LDL-C.
Limitations
- Findings derive from a prespecified subgroup; external generalizability beyond similar high-risk diabetes populations requires caution.
- Cost-effectiveness and adherence in real-world primary prevention settings were not addressed.
Future Directions: Define optimal selection criteria and cost-effectiveness for primary prevention with PCSK9 inhibitors in diabetes; assess effects in broader non-atherosclerotic high-risk groups and explore de-escalation strategies once LDL-C targets are achieved.
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis. OBJECTIVE: To investigate whether evolocumab could prevent a first major cardiovascular event (MACE) in patients without known significant atherosclerosis. DESIGN, SETTING, AND PARTICIPANTS: VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab conducted across 774 sites in 33 countries and enrolling 12 257 patients with no prior myocardial infarction or stroke, LDL-C level 90 mg/dL or greater, and qualifying atherosclerosis or high-risk diabetes. This prespecified subgroup analysis examined outcomes in patients without known significant atherosclerosis (none of the following: prior arterial revascularization, arterial stenosis ≥50%, or coronary artery calcium score ≥100 Agatston units), all of whom had diabetes. Enrollment started in June 2019 and the last patient visit was July 2025, with a median follow-up of 4.8 years.
2. Maltol induces diabetic fragility fractures by disrupting the balance of bone remodeling.
Using human tissue metabolomics with in vivo and in vitro validation, the study identifies the food additive maltol as a modifiable risk factor for diabetic skeletal fragility. Maltol suppresses osteoblastogenesis via Wnt/β-catenin and enhances osteoclast maturation via NF-κB, effects accentuated by hyperglycemia and mitigated by insulin normalization in mice.
Impact: This work uncovers a previously unrecognized diet-derived metabolite driving bone fragility in diabetes and delineates dual remodeling mechanisms, suggesting actionable, disease-specific dietary guidance.
Clinical Implications: Clinicians should recognize that metabolic context (hyperglycemia) can convert a common food additive into a skeletal risk; dietary counseling for patients with diabetes may need to consider maltol exposure while interventional human studies are pursued.
Key Findings
- Maltol accumulated in femoral neck tissue of individuals with diabetes-related fragility fractures and higher circulating maltol correlated with fracture incidence.
- Maltol inhibited osteoblast differentiation via Wnt/β-catenin and promoted osteoclast maturation via NF-κB signaling, disrupting remodeling.
- Hyperglycemia amplified maltol’s skeletal toxicity, whereas insulin normalization mitigated bone deterioration in mouse models.
Methodological Strengths
- Translational integration of human metabolomics with mechanistic in vivo and in vitro validation.
- Pathway-level causality established via modulation of Wnt/β-catenin and NF-κB and metabolic context (hyperglycemia/insulin) testing.
Limitations
- Human data are observational; sample sizes and confounder control for metabolomics are not detailed in the abstract.
- No interventional human trial demonstrating fracture risk reduction via maltol restriction.
Future Directions: Quantify dietary maltol exposure in diverse populations with diabetes, test causality in prospective cohorts and randomized dietary intervention trials, and evaluate regulatory guidance for additive exposure by metabolic status.
Type 2 diabetes is a major risk factor for fragility fractures, yet the contributors to skeletal fragility remain unclear. Through integrated clinical metabolomics, in vivo, and in vitro analyses, we identify maltol-a widely used food additive-as a previously unrecognized risk factor for hyperglycemia-associated bone fragility. Metabolomic profiling of femoral neck tissue from individuals with fragility fractures showed diabetes-associated maltol accumulation, and elevated circulating maltol levels correlated with increased fracture incidence. Mechanistically, maltol inhibits osteoblast differentiation via Wnt/β-catenin and promotes osteoclast maturation through nuclear factor κB (NF-κB) signaling, disrupting bone remodeling. These effects are amplified under hyperglycemia, while insulin reversal of glucose levels mitigates maltol-induced skeletal deterioration in mouse models. Given the widespread use of maltol in processed foods, these findings suggest that food additive safety should consider metabolic context and call for disease-specific dietary exposure guidelines to reduce fracture risk in diabetes.
3. Role of dopamine in the development of impaired counterregulation and impaired awareness of hypoglycemia.
Dopamine signaling in the ventral tegmental area critically mediates HAAF in rodents. Metoclopramide prevented and reversed impaired awareness and counterregulation, while central bromocriptine induced HAAF, nominating dopamine antagonism as a candidate therapeutic strategy.
Impact: By defining a causal neural mechanism for HAAF and identifying a clinically available antagonist that reverses it in vivo, this study opens a translational path to address a major barrier in intensive diabetes management.
Clinical Implications: If translatable, short-term, targeted dopamine antagonism could be tested to restore hypoglycemia awareness and counterregulation in patients with HAAF; careful dosing and safety monitoring would be essential.
Key Findings
- Metoclopramide prevented development of HAAF and restored impaired awareness and counterregulatory responses after HAAF induction in rodents.
- Central administration of bromocriptine induced HAAF, implicating dopamine receptor activation.
- Ventral tegmental area dopaminergic modulation bidirectionally altered CRR with matching changes in dopaminergic gene expression.
Methodological Strengths
- Use of a validated rodent HAAF model with both prevention and reversal paradigms and pharmacologic bidirectional manipulation.
- Convergent behavioral, physiologic (CRR), and molecular (VTA gene expression) endpoints supporting causality.
Limitations
- Preclinical rodent data; human neural circuitry and drug tolerability may differ.
- Metoclopramide’s peripheral and central off-target effects warrant careful translational study design.
Future Directions: Early-phase human mechanistic trials assessing dopamine antagonism on hypoglycemia awareness, CRR, and safety; neuroimaging to map VTA-circuit engagement; identification of biomarkers predicting response.
For people with diabetes, the syndrome of hypoglycemia-associated autonomic failure (HAAF) is composed of a blunted counterregulatory response (CRR) and impaired awareness of hypoglycemia (IAH). The objective herein is to identify a drug that might correct these components of HAAF. A rodent model of HAAF was developed to induce both impaired CRR and IAH (blunted food intake response to hypoglycemia). A drug screen identifies the dopamine antagonist, metoclopramide (MET), that prevents the development of HAAF. Additionally, following the induction of HAAF, MET restores normal awareness and CRRs. Conversely, the dopamine receptor agonist (bromocriptine), when administered centrally, induces HAAF. Finally, dopaminergic modulation of the ventral tegmental area (VTA) induces reciprocal changes in CRR to hypoglycemia with matching changes in VTA dopaminergic gene expression. These data identify dopamine signaling as a critical mediator of HAAF and dopamine antagonism as a potential treatment strategy.